Article Text

PDF
THU0141 Biomarker assessment of VX-509, an investigational selective JAK3 inhibitor, in healthy volunteers
  1. I.M. Catlett,
  2. X. Luo,
  3. M.S. Penney,
  4. M.E. Pray,
  5. G. Spencer-Green,
  6. M. Botfield,
  7. T. Hoock
  1. Vertex Pharmaceuticals Incorporated, Cambridge, United States

Abstract

Background The IL-2 cytokine receptor family plays an important role in lymphocyte development, survival, and T cell-mediated immune response. Janus kinase 3 (JAK3) is an integral mediator of this signaling pathway and downstream physiology through the phosphorylation of multiple substrates, including the STAT family. VX-509 is a potent, small-molecule, investigational selective inhibitor of JAK3. VX-509 is active in animal models of inflammation, including collagen-induced arthritis.

Objectives To evaluate exploratory biomarkers of JAK3 or JAK2 activity and their relationship with pharmacokinetic parameters in healthy volunteers dosed with VX-509.

Methods This was a Phase 1, double-blind, dose-escalation, placebo-controlled study. Volunteers were administered single or multiple ascending doses of VX-509 (maximum 400 mg single-dose and 150 mg q12h). Blood samples were collected to quantify VX-509 concentrations and assess experimental biomarkers of JAK activity. Blood samples were stimulated with IL-7, a JAK1/3 activator, or IL-6, a JAK1/2 activator. Phospho(p)-STAT5 or pSTAT3 respectively were measured in T cell subsets by flow cytometry. PK and PD parameters were studied using non-compartmental analysis (NCA) and PK/PD relationships were explored using an inhibitory, sigmoid effect PD model.

Results Inhibition of the JAK3-biomarker, IL-7 induced pSTAT5, was dose dependent and correlated with the concentration of VX-509. Peak pSTAT5 inhibition was reached at approximately 1 to 2 h post dose. This was consistent with the PK of VX-509, with a median tmax of approximately 1 h. Inhibition of pSTAT5 increased from Day 1 to Day 14 consistent with VX-509 exposure, and pSTAT5 inhibition was reversible. Inhibition of the JAK3 biomarker pSTAT5 was observed across the dose range, with a maximal inhibition of 89%. In contrast, measurement of IL-6-mediated pSTAT3, a JAK1/2 biomarker, was inhibited only at the highest dose, with a maximal inhibition of 54%. Inhibition of the JAK1/2-biomarker was of short duration and was also reversible. The pSTAT5 and VX-509 relationship can be well described using a simple direct sigmoid inhibitory PD model. However, pSTAT3 and VX-509 showed only weak correlation, likely due to the weak inhibitory effect of VX-509 against JAK2.

Conclusions The PK/PD correlations of the experimental biomarkers demonstrated that VX-509 is a selective, reversible inhibitor of JAK3 signaling in humans. VX-509 warrants further clinical investigation in patients with chronic, immune-mediated inflammatory disorders, including rheumatoid arthritis.

Disclosure of Interest I. Catlett Shareholder of: Vertex Pharmaceuticals, Employee of: Vertex Pharmaceuticals, X. Luo Shareholder of: Vertex Pharmaceuticals, Employee of: Vertex Pharmaceuticals, M. Penney Shareholder of: Vertex Pharmaceuticals, Employee of: Vertex Pharmaceuticals, M. Pray Shareholder of: Vertex Pharmaceuticals, Employee of: Vertex Pharmaceuticals, G. Spencer-Green Shareholder of: Vertex Pharmaceuticals, Employee of: Vertex Pharmaceuticals, M. Botfield Shareholder of: Vertex Pharmaceuticals, Employee of: Vertex Pharmaceuticals, T. Hoock Shareholder of: Vertex Pharmaceuticals, Employee of: Vertex Pharmaceuticals

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.